I've made a fortune! Novo Nordisk announces Q4 financial report. Weight loss drug Wegovy's annual revenue has doubled
centery0918112
发表于 2024-1-31 17:41:18
3518
0
0
European pharmaceutical giant Novo Nordisk released its Q4 2023 financial report on Wednesday, with its revenue performance exceeding market expectations. It also predicts that it will continue to achieve double-digit sales growth this year, with the biggest contributor being its newly launched weight loss drug Wegovy.
According to the financial report, in Danish kroner terms, Novo Nordisk's revenue increased by 31% in 2023 to 232.3 billion kroner (approximately 33.7 billion US dollars), far exceeding market expectations of 21%, and the company's revenue in North America grew strongly by 50%.
In addition, Novo Nordisk's operating profit increased by 37% to 102.6 billion kroner, and its net profit increased by 51% year-on-year to 83.683 billion kroner.
The most eye-catching diabetes and obesity service revenue increased by 38% last year, with GLP-1 drug sales in diabetes increasing by 48% and obesity increasing by 147%.
The company's outlook is that its revenue will continue to grow in 2024, with a growth rate adjusted for fixed exchange rates ranging from 18% to 26%; Meanwhile, profits will also increase by 21-29%. This expectation shows that Novo Nordisk has extremely optimistic sales confidence and is optimistic about market demand.
Lars Fruergaard Jorgensen, CEO of the company, expressed in a statement that he is very pleased with the strong financial performance in 2023. Currently, over 40 million people worldwide are benefiting from Novo Nordisk's innovative diabetes and obesity treatment plans.
Celebrity weight loss pills
Novo Nordisk pointed out in its financial report that the revenue of GLP-1 drugs (Rybelsus, Ozempic, and Vitoza) used solely for the treatment of type 2 diabetes increased by 48% last year (in Danish kroner), reaching 123.1 billion kroner.
In the global diabetes market, the share of GLP-1 drugs has also increased by 6% from 4.5% a year ago, with Novo Nordisk accounting for 54.8% of the GLP-1 drug market, making it the undisputed leader.
And the star product Ozempic, the low-dose version of Wegovy, saw a 60% increase in sales last year. Novo Nordisk believes that this growth is related to phased supply restrictions and different regions' preventive attitudes towards drug shortages.
The weight loss market is even hotter, with Wegovy, which even Musk is using, experiencing a sales growth of 407% in 2023. The financial report shows that the drug has been launched in countries such as the United States, Denmark, Norway, Germany, the United Kingdom, Iceland, Switzerland, and the United Arab Emirates, with a market size expanding by 116% compared to 2022.
Helge Lund, Chairman of Novo Nordisk, stated in his financial report that the increasing prevalence of type 2 diabetes and obesity has led to a surge in demand for GLP-1 drugs. It also pointed out that this enabled Novo Nordisk to reach the largest user base in its century old history, accelerating strong growth in North American and international business.
On this basis, Novo Nordisk stated that it will vigorously invest in expanding production capacity. In 2023 alone, the company has announced that it will invest over 75 billion Danish kroner (approximately 10.9 billion US dollars) to expand its global base. In addition, the company also stated that in addition to the construction project, Novo Nordisk has implemented a 7-day, 24-hour, three shift extreme production system to meet market demand.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Micron's financial report is exciting! The stock price surged by over 14% after the market closed, and the next quarter's performance guidance exceeded expectations comprehensively
- Top 20 US stock transactions: Micron Technology's impressive financial report saw a post market increase of over 13%
- Is winter really coming? Micron's financial report hits face, leading to a collective frenzy of global chip stocks
- Boeing's first financial report since new CEO takes office: Q3 loss expands by 277% year-on-year, aircraft deliveries cut by 11
- On the evening of October 31st at 8pm, JD's "11 · 11" officially kicked off with doubled subsidies
- JD.com officially doubles subsidy for 11.11 opening ceremony
- Just now! Apple releases financial report, iPhone business shows stable performance, Greater China business under pressure
- After the friction between Qualcomm and Arm, the first financial report has been released, and the mobile phone related business has entered a period of recovery
- Tmall: 1100 Tmall 3C digital brand transactions doubled during Double 11 period
- Tmall: 7062 clothing brands' transactions doubled year-on-year during Double 11 period
-
据媒体报道,OpenAI正准备推出一款代号为“Operator”的全新AI助理产品,可以自动执行各种复杂操作,包括编写代码、预订旅行、自动电商购物等。根据内部员工爆料,OpenAI领导层预计将在2025年1月发布该产品,首 ...
- 永远的希望
- 昨天 11:06
- 支持
- 反对
- 回复
- 收藏
-
【小摩辣评“特朗普2.0”:关税大棒料打击经济、重燃通胀!】摩根大通资产管理公司(JPMorgan Asset Management)首席全球市场策略师David Kelly周三表示,当选总统特朗普激进的关税计划,可能会减缓全球经济,并给 ...
- besharp
- 昨天 12:37
- 支持
- 反对
- 回复
- 收藏
-
本报讯 (记者李豪悦)11月12日,腾讯音乐娱乐集团(以下简称“腾讯音乐”)宣布其截至2024年9月30日止第三季度的未经审计财务业绩。 2024年第三季度,腾讯音乐娱乐集团业绩表现稳健,总收入为70.2亿元,同 ...
- 覃志辉
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
新华财经上海11月13日电芯片制造商英伟达和软银集团的电信部门软银公司周三表示,两家公司已经试运行了全球首个人工智能和5G电信网络。 两家公司表示,该网络可以同时运行人工智能和5G工作负载,这一过程被 ...
- 惡魔獵人
- 前天 12:36
- 支持
- 反对
- 回复
- 收藏